Non Hodgkin Lymphoma Clinical Trial
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Summary
The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
Full Description
NOTE: Currently, this study is only open to nivolumab+daratumumab vs daratumumab monotherapy in multiple myeloma patients.
Eligibility Criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Have received at least 3 prior lines of therapy, including a proteasome inhibitor [PI] and an immunomodulatory agent [IMiD] OR have disease that is double refractory to a PI and IMiD
More than 12 weeks post-transplant of your own blood forming stem cells (autologous transplant)
Have detectable disease measured by a specific protein in your blood and/or urine
Must consent to bone marrow aspirate or biopsy.
Exclusion Criteria:
Solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia, or monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), primary amyloidosis, Waldenstrom's macroglobulinemia, POEMS syndrome or active plasma cell leukemia
Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti CTLA 4, or anti-CD38 antibody, or allogeneic stem cell transplantation
Seropositive for human immunodeficiency virus (HIV), Hepatitis B surface antigen or Hepatitis C antibody positive (except if HCV-RNA negative), or history of active chronic hepatitis B or C
History of central nervous system involvement or symptoms suggestive of central nervous system involvement by multiple myeloma
Other protocol defined inclusion/exclusion criteria could apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 31 Locations for this study
Clovis California, 93611, United States
Los Angeles California, 90095, United States
Los Angeles California, 90095, United States
Aurora Colorado, 80045, United States
New Haven Connecticut, 06520, United States
Orlando Florida, 32804, United States
Skokie Illinois, 60077, United States
Indianapolis Indiana, 46202, United States
Westwood Kansas, 66205, United States
Baltimore Maryland, 21231, United States
Baltimore Maryland, 21231, United States
Boston Massachusetts, 02215, United States
Boston Massachusetts, 02215, United States
Boston Massachusetts, 02215, United States
Ann Arbor Michigan, 48109, United States
Ann Arbor Michigan, 48109, United States
Rochester Minnesota, 55905, United States
Rochester Minnesota, 55905, United States
Omaha Nebraska, 68130, United States
Hackensack New Jersey, 07601, United States
Hackensack New Jersey, 07601, United States
New York New York, 10065, United States
New York New York, 10065, United States
Columbus Ohio, 43210, United States
Portland Oregon, 97239, United States
Portland Oregon, 97239, United States
Philadelphia Pennsylvania, 19104, United States
Philadelphia Pennsylvania, 19104, United States
Philadelphia Pennsylvania, 19111, United States
Philadelphia Pennsylvania, 19111, United States
Salt Lake City Utah, 84112, United States
Salt Lake City Utah, 84112, United States
Gent , 9000, Belgium
Sint-Niklaas , 9100, Belgium
Yvoir , B-553, Belgium
Poitiers Vienne, 86021, France
Nantes Cedex 1 , 44000, France
Athens , 11528, Greece
Bologna , 40138, Italy
Chorzow , 41-50, Poland
Poznan , 61-84, Poland
Warszawa , 02-77, Poland
Wroclaw , 50-36, Poland
How clear is this clinincal trial information?